Vertex upgraded to Buy from Neutral at UBS UBS upgraded Vertex based on increased confidence that the lumicaftor-ivacaftor combination will be successful in 2014 Phase 3 readouts in cystic fibrosis. Price target raised to $99 from $84.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Vertex shares should be owned ahead of data, says JMP Securities JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.